Five advanced pancreatic cancer patients in a Phase I study of anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (BATS)

Lawrence G Lum; Minsig Choi; Archana Thakur; Abhinav Deol; Kristie Fields; Elyse Tomaszewski; Dana Schalk; Vidya Kondadasule; Greg Dyson; Hemchandra Mahaseth; Philip Philip; Anthony Shields

首页> 外文期刊>Journal for ImmunoTherapy of Cancer >Five advanced pancreatic cancer patients in a Phase I study of anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (BATS)

【24h】

Five advanced pancreatic cancer patients in a Phase I study of anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (BATS)

机译：五名晚期胰腺癌患者在抗CD3 x抗EGFR双特异性抗体武装的活化T细胞（BATS）的I期研究中

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal for ImmunoTherapy of Cancer 》 |2015年第s2期| 共页
作者
Lawrence G Lum; Minsig Choi; Archana Thakur; Abhinav Deol; Kristie Fields; Elyse Tomaszewski; Dana Schalk; Vidya Kondadasule; Greg Dyson; Hemchandra Mahaseth; Philip Philip; Anthony Shields;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学 ;
关键词

相似文献

外文文献
中文文献
专利

1. Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients [J] . Lum, L.G., Thakur, Oncoimmunology. . 2020 ,第1期

机译：抗CD3 X抗EGFR双特异性抗体武装活化T细胞（EGFR蝙蝠）在胰腺癌患者中的临床和免疫应答
2. Vaccination with bispecific antibody armed T cells (BATC) in metastatic breast cancer patients and transfer of anti-breast cancer immunity in primed T cells after stem cell transplant: a proof of principle study [J] . Archana Thakur, Lawrence G Lum, Vidya Kondadasule, Journal for ImmunoTherapy of Cancer . 2015 ,第S2期

机译：在转移性乳腺癌患者中用双特异性抗体武装T细胞（BATC）进行疫苗接种以及干细胞移植后初免T细胞中抗乳腺癌免疫力的转移：原理研究的证明
3. Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy [J] . Bannerji Rajat, Brown Jennifer R., Advani Ranjana H., Blood: The Journal of the American Society of Hematology . 2016 ,第22期

机译：REGN1979（一种抗CD20 x抗CD3双特异性单克隆抗体）在先前用CD20定向抗体疗法治疗的CD20 + B细胞恶性肿瘤患者中的1期研究
4. Improved T Cell Activation Bioassays to Advance the Development of Bispecific Antibodies and Engineered T Cell Immunotherapies [C] . Gopal Krishnan, Pete Stecha, Denise Garvin, Protein Engineering Summit. . 2018

机译：改进的T细胞活化生物测定促进双特异性抗体和工程化T细胞免疫检查的发育
5. CD16xCD33 bispecific killer cell engager (BiKE) activates natural killer (NK) cells from myelodysplastic syndrome (MDS) patients against primary MDS and myeloidderived suppressor cell (MDSC) CD33-positive targets. [D] . Gleason, Michelle K. 2014

机译：CD16xCD33双特异性杀伤细胞接合剂（BiKE）激活来自骨髓增生异常综合征（MDS）患者的自然杀伤（NK）细胞，以抵抗原发性MDS和髓样抑制细胞（MDSC）CD33阳性靶标。
6. Five advanced pancreatic cancer patients in a Phase I study of anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (BATS) [O] . Lawrence G Lum, Minsig Choi, Archana Thakur, 2015

机译：五名晚期胰腺癌患者在抗CD3 x抗EGFR双特异性抗体武装的活化T细胞（BATS）的I期研究中
7. Five advanced pancreatic cancer patients in a Phase I study of anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (BATS) [O] . 2015

机译：五名晚期胰腺癌患者在抗CD3 x抗EGFR双特异性抗体武装的活化T细胞（BATS）的I期研究中
8. Cell Penetrating Bispecific Antibodies for Targeting Oncogenic Transcription Factors in Advanced Prostate Cancer. [R] . Lilly, M., Weisbart, R. 2016

机译：细胞穿透双特异性抗体靶向晚期前列腺癌的致癌转录因子。

Five advanced pancreatic cancer patients in a Phase I study of anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (BATS)

著录项

相似文献

相关主题

期刊订阅